CLDX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CLDX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Celldex Therapeutics's Shareholder Yield % was -16.31%.
The historical data trend for Celldex Therapeutics's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celldex Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Shareholder Yield % | Get a 7-Day Free Trial | -25.60 | 0.20 | 0.03 | -0.03 | 0.02 |
Celldex Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Shareholder Yield % | Get a 7-Day Free Trial | -0.06 | -0.03 | -0.01 | 0.02 | -62.47 |
For the Biotechnology subindustry, Celldex Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Celldex Therapeutics's Shareholder Yield % falls into.
Celldex Therapeutics's Shareholder Yield % for the quarter that ended in Mar. 2024 is calculated as:
Shareholder Yield % | = | Dividend Yield % | + | Buyback Yield % | + | Net Debt Paydown Yield % |
= | 0 % | + | -62.51 % | + | 0.04 % | |
= | -62.47 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Celldex Therapeutics (NAS:CLDX) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Thank you for viewing the detailed overview of Celldex Therapeutics's Shareholder Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Garry Arthur Neil | director | 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104 |
Cheryl Cohen | director | C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105 |
Rita Jain | director | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142 |
Tibor Keler | officer: Sen. VP & Ch Scientific Off. | 30 PARK ROAD, OTTSVILLE PA 18942 |
Sarah Cavanaugh | officer: SVP of Corp. Affairs & Admin. | C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827 |
Diane C. Young | officer: SVP, Chief Medical Officer | 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103 |
Anthony S Marucci | director, officer: President and CEO | 66 COLD HILL DRIVE, MENDAHM NJ 07945 |
Richard M. Wright | officer: Sr. VP & CCO | C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827 |
Samuel Bates Martin | officer: SVP and CFO | C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827 |
Margo Heath-chiozzi | officer: SVP of of Regulatory Affairs | C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827 |
Elizabeth Crowley | officer: SVP, Chief Product Dev Officer | C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827 |
Freddy A. Jimenez | officer: SVP & General Counsel | C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827 |
James J Marino | director | C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940 |
Keith L Brownlie | director | 777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591 |
Gerald Phd Mcmahon | director | 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114 |
From GuruFocus
By sperokesalga sperokesalga • 02-16-2023
By Marketwired • 09-26-2023
By Marketwired • 07-11-2023
By PurpleRose PurpleRose • 07-11-2022
By PurpleRose PurpleRose • 07-21-2022
By GlobeNewswire GlobeNewswire • 06-10-2023
By GlobeNewswire • 11-08-2023
By Value_Insider Value_Insider • 11-10-2022
By sperokesalga sperokesalga • 02-15-2023
By Value_Insider Value_Insider • 12-02-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.